Aslan Presents Progress Update on its Three Clinical Candidates
publication date: Aug 13, 2019
Aslan Pharma of Singapore provided an update on the progress of its three clinical-stage oncology and immunology candidates:
• The company signed up K-MASTER to run a 400 patient South Korean Phase Ib/II trial of its lead drug, varlitinib, in patients with metastatic gastric cancer.
• ASLAN003 started a four-arm Phase II clinical trial for advanced relapsed/refractory acute myeloid leukemia;
• Aslan acquired global rights to ASLAN004 for all indications from CSL in a $780 million deal. Previously, Aslan had global rights only for asthma.
Stock Symbols: (NSDQ: ASLN, TPEx:6497)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.